TILT Biotherapeutics Ltd.

Privately held: no public share price · Finland

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
Tumor cells (oncolytic replication via Ad3 receptor); expresses TNF-alpha and IL-2Oncolytic virus
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
Igrelimogene litadenorepvecPhase 1/2Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma …
Est. primary completion 2027-03 · NCT05271318 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.